NV-VPAC1

N/A

Report date: 2025/11/20 16:01:03

NME

Base Information

Drug NameNV-VPAC1

Drug Alias Name64Cu-TP-3805Cu64-TP-3805Cu64-NLS-VPAC1TP-3805NLS-VPAC1 +[7]

ClassificationDiagnostic agent (In vivo)Radiation-emitting products > Nuclides > Copper > 64CuRadiation-emitting products > Radionuclide Drug Conjugates +[5]

Mechanisms of ActionVasoactive intestinal polypeptide receptor 1 agonistsPositron-emission tomography enhancersRadionuclide imaging enhancers +[4]

TargetsVasoactive intestinal polypeptide receptor 1

Therapy Area/IndicationsProstatic NeoplasmsCarcinoma, Transitional Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesThomas Jefferson University

China Registration ClassN/A

Develop Information

Active CompaniesSidney Kimmel Cancer Center At Thomas Jefferson University

Inactive CompaniesN/A

Active IndicationsCarcinoma, Transitional Cell

Inactive IndicationsProstatic Neoplasms

Other Information

ATC CodeN/A